WATCH NOW
Lexeo Therapeutics | September 2026
On September 25, 2026, Dr. Gregory Aubert, VP of Clinical Development at Lexeo, and Dr. Theresa Zesiewicz, Director of the Ataxia Research Center at the University of South Florida, shared information about Lexeo’s SUNRISE-FA 2 investigational gene therapy trial, a late-stage clinical trial to evaluate whether LX2006 may improve heart function and limit the progression of Friedreich ataxia cardiomyopathy (FA-CM).
This recording does not include the Q&A portion of the webinar.
